DUBLIN--(BUSINESS WIRE)--The "Bacterial (Pyogenic) Meningitis - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
'Bacterial (Pyogenic) Meningitis - Pipeline Insight, 2018 report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Bacterial (Pyogenic) Meningitis development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:
- Clinical
- Non-clinical
- Inactive: Discontinued and/or Dormant
Descriptive coverage of pipeline development activities for Bacterial (Pyogenic) Meningitis
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
The report assesses the active Bacterial (Pyogenic) Meningitis pipeline products by developmental stage, product type, molecule type, and administration route.
Key Topics Covered:
1. Report Introduction
2. Bacterial (Pyogenic) Meningitis Overview
3. Pipeline Therapeutic
4. Comparative Analysis
5. Products in Clinical Stage
6. Products in Pre-Clinical and Discovery Stage
7. Therapeutic Assessment
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
8. Inactive Products
Companies Mentioned
- AstraZeneca
- Sanofi Pasteur
- GlaxoSmithKline
- Beijing Zhifei Lvzhu Biopharmaceutical Co. Ltd
- Aberabio
- Novartis
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/brn7fw/bacterial?w=4
